Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Assertio Therapeutics Inc

Healthcare US ASRT

23.5USD
0.00(0%)

Last update at 2026-06-23T13:30:00Z

Day Range

23.5023.50
LowHigh

52 Week Range

8.6120.45
LowHigh

Fundamentals

  • Previous Close 23.50
  • Market Cap116.32M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA12.78M
  • Revenue TTM118.71M
  • Revenue Per Share TTM18.54
  • Gross Profit TTM 83.33M
  • Diluted EPS TTM-4.74

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -29.94000M -21.52900M -254.05400M 31.17M -0.55300M
Minority interest - - - - -
Net income -29.50500M -21.58100M -331.94200M 109.62M -1.28100M
Selling general administrative 69.00M 75.15M 65.34M 46.79M 56.55M
Selling and marketing expenses - 1.80M 4.40M - -
Gross profit 83.33M 85.73M 125.05M 137.49M 95.18M
Reconciled depreciation 30.00M 25.83M 28.23M 33.40M 29.08M
Ebit -17.22300M -20.68300M 24.94M 57.81M 9.42M
Ebitda 12.78M 5.15M 53.17M 91.21M 39.83M
Depreciation and amortization 30.00M 25.83M 28.23M 33.40M 30.41M
Non operating income net other - - - - -
Operating income -21.53600M -24.47600M -243.53600M 57.81M 9.42M
Other operating expenses 140.25M 149.44M 395.61M 98.14M 100.50M
Interest expense 3.08M 3.04M 3.38M 7.96M 10.22M
Tax provision 0.43M 0.05M 77.89M -78.45900M 0.73M
Interest income 2.67M 3.22M 2.40M - -
Net interest income -0.41000M 0.18M -13.29800M -7.96100M -10.22000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.43500M 0.05M 77.89M -78.45900M 0.73M
Total revenue 118.71M 124.96M 152.07M 156.23M 111.01M
Total operating expenses 104.87M 110.21M 368.58M 79.39M 84.67M
Cost of revenue 35.38M 39.23M 27.02M 18.75M 15.83M
Total other income expense net -8.40400M 2.95M -10.51800M -26.64800M -9.97700M
Discontinued operations - - - - -
Net income from continuing ops -30.37500M -21.58100M -331.94200M 109.62M -1.28100M
Net income applicable to common shares - - - 109.62M -1.28100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 266.97M 284.73M 286.42M 413.91M 326.55M
Intangible assets 48.91M 80.47M 111.33M 198.00M 216.05M
Earning assets - - - - -
Other current assets 9.01M 10.07M 12.27M 8.27M 14.84M
Total liab 173.02M 163.65M 148.42M 188.19M 224.13M
Total stockholder equity 93.95M 121.08M 138.00M 225.72M 102.41M
Deferred long term liab - - - - -
Other current liab 118.50M 99.62M 79.08M 88.86M 48.80M
Common stock 0.00100M 0.00900M 0.00900M 0.00500M 0.00400M
Capital stock 0.00100M 0.00900M 0.00900M 0.00500M 0.00400M
Retained earnings -703.49900M -673.12400M -651.54300M -319.60100M -429.22600M
Other liab - - - 26.47M 27.80M
Good will - - - - -
Other assets - - 0.00000M 82.51M 5.47M
Cash 10.23M 50.59M 73.44M 64.94M 36.81M
Cash and equivalents - - - - -
Total current liabilities 127.51M 114.69M 93.44M 95.32M 135.02M
Current deferred revenue - - - - 67.36M
Net debt 28.89M -10.32200M -32.52900M 1.93M 36.68M
Short term debt - 0.33M 0.93M 0.47M 12.17M
Short long term debt - - - 0.47M 12.17M
Short long term debt total 39.12M 40.27M 40.91M 66.87M 73.49M
Other stockholder equity 797.45M 794.20M 789.54M 545.32M 531.64M
Property plant equipment - - - 0.88M 1.53M
Total current assets 216.65M 202.55M 171.06M 132.26M 103.50M
Long term investments - - - 0.27M 1.58M
Net tangible assets - - - 27.73M -113.64000M
Short term investments 53.18M 49.47M - - -
Net receivables 120.11M 54.12M 47.66M 45.36M 44.36M
Long term debt 39.12M 38.65M 38.21M 66.40M 61.32M
Inventory 24.12M 38.31M 37.69M 13.70M 7.49M
Accounts payable 9.01M 14.74M 13.44M 5.99M 6.68M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.97M 0.00100M 1.99M 2.44M 5.47M
Deferred long term asset charges - - - - -
Non current assets total 50.32M 82.18M 115.36M 281.65M 223.05M
Capital lease obligations 0.89M 1.12M 1.47M - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -3.81400M -48.91100M 3.10M -42.67300M -18.52500M
Change to liabilities - - - -10.20800M -28.69900M
Total cashflows from investing activities -11.98800M -48.91100M 3.10M -42.67300M -18.52500M
Net borrowings - 0.00000M -10.50000M -0.75000M -9.83500M
Total cash from financing activities -0.18900M -0.35000M -44.20100M -7.79400M 29.03M
Change to operating activities - - - 4.78M -7.37300M
Net income -30.37500M -21.58100M -331.94200M 109.62M -1.28100M
Change in cash -40.35900M -22.85300M 8.50M 28.13M 16.02M
Begin period cash flow 50.59M 73.44M 64.94M 36.81M 20.79M
End period cash flow 10.23M 50.59M 73.44M 64.94M 36.81M
Total cash from operating activities -28.18200M 26.41M 49.60M 78.60M 5.52M
Issuance of capital stock - - 0.00000M 7.02M 44.86M
Depreciation 30.00M 25.83M 28.23M 33.40M 29.08M
Other cashflows from investing activities -8.17400M - -0.41900M - -
Dividends paid - - - - -0.19300M
Change to inventory 9.68M -9.58300M -4.97300M -6.59300M 4.27M
Change to account receivables -65.99000M -6.45700M 48.67M -0.99600M -0.01100M
Sale purchase of stock -0.18900M -0.35000M -7.89800M -0.87200M -0.41800M
Other cashflows from financing activities -0.18900M -0.35000M -25.80300M 56.81M -5.38900M
Change to netincome - - - -51.71300M 8.83M
Capital expenditures 0.00000M 0.00000M 0.63M 0.27M 0.05M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -45.33300M 5.20M 0.14M -13.01400M -31.29300M
Stock based compensation 3.45M 5.01M 9.16M 7.50M 3.54M
Other non cash items 14.07M 11.95M 267.82M 21.46M 4.11M
Free cash flow -28.18200M 26.41M 48.98M 78.32M 5.47M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ASRT
Assertio Therapeutics Inc		 - -% 23.50 - 588.24 0.98 1.25 0.79 35.18
ZTS
Zoetis Inc		 1.33 1.73% 78.17 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.96 3.11% 31.85 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 155.71 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 1.58 3.64% 45.00 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Assertio Therapeutics Inc

100 South Saunders Road, Lake Forest, IL, United States, 60045

Key Executives

Name Title Year Born
Mr. Daniel A. Peisert Pres, CEO & Director 1975
Mr. Paul Schwichtenberg Sr. VP & CFO 1971
Mr. Ajay Patel Sr. VP & Chief Accounting Officer 1984
Mr. Bill Iskos Sr. VP of Operations NA
Dr. Jack Hoblitzell Ph.D. Sr. VP of Technical Operations NA
Mr. Sam Schlessinger Sr. VP & Gen. Counsel NA
Mr. Jeff Christensen Sr. VP of Commercial NA
Ms. Heather L. Mason Interim CEO & Director 1960
Mr. Ajay Patel Senior VP & CFO 1985
Mr. Paul Schwichtenberg Senior Vice President & Chief Commercial Officer 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions